|
Volumn 152, Issue 2, 2005, Pages 380-382
|
Role of Mycobacterium w vaccine in the management of psoriasis [10]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
EMOLLIENT AGENT;
INACTIVATED VACCINE;
MYCOBACTERIUM VACCINE;
TOPICAL AGENT;
ABSCESS;
ADULT;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
HUMAN;
IMMUNOMODULATION;
INJECTION SITE REACTION;
LETTER;
MALE;
NECROSIS;
PRIORITY JOURNAL;
PSORIASIS;
SCAR FORMATION;
SKIN INDURATION;
TREATMENT OUTCOME;
ADULT;
BACTERIAL VACCINES;
FEMALE;
HUMANS;
MALE;
MIDDLE AGED;
MYCOBACTERIUM;
PSORIASIS;
SEVERITY OF ILLNESS INDEX;
TREATMENT OUTCOME;
|
EID: 14844323962
PISSN: 00070963
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1365-2133.2005.06343.x Document Type: Letter |
Times cited : (8)
|
References (11)
|